H2020Индивидуална стипендия2018–2020

TET2rec · Mechanisms of TET2 DNA demethylase recruitment to specific genomic regions

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2018-03-01 → 2020-02-29
Финансиране от ЕС: 200 195 €
Участници: 1
Схема: MSCA-IF-EF-ST

Линиите свързват координатора с партньорите.

Накратко на български

Механизмите, чрез които протеинът TET2 се свързва със специфични участъци от ДНК, са основният обект на анализ. Разбирането на този процес помага да се разбере как се развива острия миелоиден лейкемия и как работят някои лекарства за лечението ѝ.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Mechanisms of TET2 DNA demethylase recruitment to specific genomic regions

Acute myeloid leukemia (AML) patients frequently harbor mutations in the epigenetic modifier TET2, which is a DNA demethylase. DNA methylation is an epigenetic modification that occurs predominantly at CpG dinucleotides and have a major impact on transcription. Accordingly, it plays key roles in cellular identity specification, and, when deregulated, in cancer. The importance of DNA methylation in cancer is underscored by the clinical use of hypomethylating agents in the treatment of AML and other myeloid disorders. DNA methylation is a reversible process and, only recently, it was discovered that TET (Ten-eleven Translocation) proteins mediate DNA demethylation. Jawed vertebrates have three TET homologues (TET1, TET2 and TET3). All TET proteins contain a C-terminal catalytic region. Remarkably, while TET1 and TET3 share an N-terminal DNA binding domain (CXXC motif), TET2 has lost its CXXC motif during evolution. Therefore, it is not understood how TET2 binds DNA. The main goal of this project is to understand how TET2 binds to specific regions of the genome.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

TET2 (Tet Methylcytosine Dioxygenase 2) is a DNA demethylase frequently mutated in patients with Acute Myeloid Leukemia (AML). DNA methylation is an epigenetic modification with key roles in the specification of cellular identity, and, when deregulated, in cancer. DNA methylation is a reversible process and, only recently, it was discovered that TET (Ten-eleven Translocation) proteins mediate DNA demethylation. Mammals have three TET homologues (TET1-3). While TET1 and TET3 share an N-terminal DNA-binding domain (CXXC motif), TET2 has lost its CXXC motif during evolution. Therefore, it is not understood how TET2 binds DNA. Due to the lack of a known DNA-binding domain in TET2, I hypothesize that TET2 may require to interact with proteins to be recruited to DNA, which is essential for its function. Hence, the main goal of my proposal is to understand how TET2 binds to DNA and to identify interacting proteins that participate in this recruitment. I also aim to unveil whether cancer-associated mutations affect TET2 recruitment.To achieve these goals, I will perform a structural-functional analysis of TET2. First, I will perform Chromatin Immunoprecipitation (ChIP) followed by whole genome sequencing of wildtype and truncated TET2. Thus, I will identify the region(s) required for the binding of TET2 to DNA. Next, I will seek proteins that interact with TET2 through the previously identified region by Mass Spectrometry and I will test their involvement in TET2 recruitment to DNA. Furthermore, I will perform similar experiments to inspect the impact of TET2 missense mutations found in human cancer on TET2 recruitment to DNA.Altogether, this project will yield a better understanding of how TET2 is recruited to DNA. The results obtained will significantly impact the epigenetic field and allow for a better understanding of the mechanisms by which TET2 exerts its function in normal cells and how TET2 mutations contribute to cancer.

Оригинален текст от CORDIS (на английски).

Участници

KOBENHAVNS UNIVERSITET · KOBENHAVNКоординаторДания